Vertex Pharmaceuticals Incorporated (VRTX) News

Vertex Pharmaceuticals Incorporated (VRTX)

Today's Latest Price: $207.01 USD

1.33 (-0.64%)

Updated Oct 29 4:00pm

Add VRTX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

Filter VRTX News Items

VRTX News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators

BOSTON--(BUSINESS WIRE)-- #ECFS2020--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data from the company’s portfolio of cystic fibrosis (CF) medicines will be presented at the 43rd European Cystic Fibrosis Digital Conference (ECFS) held September 24-25, 2020 and the 2020 North American Cystic Fibrosis Virtual Conference (NACFC) taking place October 7-23, 2020. An oral presentation at the ECFS Digital Conference will highlight, for the first time, interim results from the TRIKAFTA

Business Wire | September 24, 2020

Crispr: The Frontier Of Gene Editing

The greatest investment reward comes to those who by good luck or good sense find the occasional company that over the years can grow far more than the industry as a whole. - Phillip Fisher (Warren Buffett's mentor asides from Ben Graham) As you can see, biotech is a lucrative...

BioSci Capital Partners on Seeking Alpha | September 18, 2020

The Daily Biotech Pulse: Moderna Inks 2 R&D Deals, BioNTech To Buy Manufacturing Facility, Dyne Therapeutics IPO

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 16) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) (the first subject has been dosed in a Phase 3 trial evaluating etrasimod for the potential treatment of moderately to severely active ulcerative colitis) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) Checkpoint Therapeutics Inc (NASDAQ: CKPT ) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) (announced a deal with Russia for 100 million doses of Sputnik-V vaccine against the coronavirus) Fortress Biotech (NASDAQ: FBIO ) Guardant Health Inc (NASDAQ: GH ) Immunovant Inc (NASDAQ: IMVT ) Insmed Incorporated (NASDAQ: INSM ) InVitae Corp (NYSE: NVTA ) ...

Benzinga | September 17, 2020

Thinking about buying stock in Delta Air Lines, Scientific Games, GameStop, Vertex Pharmaceuticals, or Fortress Biotech?

NEW YORK, Sept. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DAL, SGMS, GME, VRTX, and FBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | September 14, 2020

Vertex Announces European Medicines Agency Type II Variation Marketing Authorization Application Validation for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination with ivacaftor in People with One Copy of the F508del Mutation

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the European Medicines Agency (EMA) has validated a Type II Variation Marketing Authorization Application (MAA) for the expanded indication of KAFTRIO®* (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. If approved, eligible

Business Wire | September 14, 2020

Vertex Pharmaceuticals reports 7.1% stake in Kymera Therapeutics

Vertex Pharmaceuticals (VRTX) acquires ~3.15M shares of Kymera Therapeutics (KYMR), representing 7.1% of its total shares outstanding.Shares were acquired pursuant to Vertex’s collaboration with Kymera and in a private placement that was closed concurrently with the closing of Kymera’s IPO on August 25, 2020.Vertex had paid an initial consideration of...

Seeking Alpha | September 3, 2020

Vertex Pharmaceuticals Incorporated 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2020 Q2 earnings call....

SA Transcripts on Seeking Alpha | July 31, 2020

Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call Transcript

Vertex Pharmaceuticals, Inc. (VRTX) Q2 2020 Earnings Conference Call July 30, 2020, 5:30 PM ET Company Participants Michael Partridge - SVP, IR Reshma Kewalramani - CEO, President & Director Stuart Arbuckle - EVP & Chief Commercial Officer Charles Wagner - EVP & CFO Conference Call Participants Cory Kasimov - JPMorgan...

SA Transcripts on Seeking Alpha | July 31, 2020

Vertex (VRTX) Q2 Earnings & Sales Beat, Revenue Guidance Up

Vertex (VRTX) raises its revenue guidance on the strong uptake of its newest CF drug, Trikafta. Shares rise in after-hours trading.

Yahoo | July 31, 2020

How Vertex Pharmaceuticals Wowed With Its Q2 Results

Vertex Pharmaceuticals (NASDAQ: VRTX) has been on a roll so far in 2020. The company announced its second-quarter results after the market closed on Thursday. It looks like Vertex's good times will keep rolling.

Yahoo | July 31, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.5819 seconds.